Claims for Patent: 9,884,051

Summary for Patent: 9,884,051

Title:	Demethylpenclomedine analogs and their use as anti-cancer agents
Abstract:	This disclosure concerns novel demethylpenclomedine analogs. Also disclosed are pharmaceutical compositions and methods for using such compositions to treat hyperproliferative disorders. In one embodiment the analogs are represented by the formula ##STR00001##
Inventor(s):	Morgan; Lee Roy (New Orleans, LA)
Assignee:	Dekk-Tec, Inc. (New Orleans, LA)
Application Number:	15/238,144
Patent Claims:	1. A method for treating a subject having brain and/or breast cancer, comprising administering to the subject a therapeutically effective amount of a compound of the formula ##STR00019## or a pharmaceutically acceptable salt, wherein R is methyl; X is O; G is --C(O)OR.sup.2; and R.sup.2 is a steroid ring structure. 2. The method of claim 1, comprising administering from about 1 mg/m.sup.2 to about 200 mg/m.sup.2 to the subject per day. 3. The method of claim 1, comprising administering from about 5 mg/m.sup.2 to about 100 mg/m.sup.2 to the subject per day. 4. The method of claim 1, comprising administering from about 10 mg/m.sup.2 to about 50 mg/m.sup.2 to the subject per day. 5. The method of claim 1, wherein the brain cancer comprises a brain tumor. 6. The method of claim 1, wherein the brain cancer comprises a metastatic cancer of the brain. 7. The method of claim 1, wherein the method comprises treating the subject for at least one of metastatic breast cancer and leukemia to the brain. 8. The method of claim 1, further comprising administering a second compound to the subject. 9. The method of claim 8, wherein the second compound is selected from microtubule binding agents, DNA intercalators, DNA alkylating agents, DNA cross-linkers, DNA synthesis inhibitors, DNA and/or RNA transcription inhibitors, enzyme inhibitors, gene regulators, enzymes, antibodies and angiogenesis inhibitors. 10. The method of claim 8, wherein the second compound is selected from erlotinib, gefitinib, temozolomide, paclitaxel, docetaxel, daunorubicin, cisplatin, carboplatin, oxaliplatin, colchicine, dolastatin 15, nocodazole podophyllotoxin, rhizoxin, vinblastine, vindesine, vinorelbine (navelbine), the epothilones, the mitomycins, bleomycin, chlorambucil, carmustine, melphalan, mitoxantrone, 5-fluoro-5'-deoxyuridine, camptothecin, SFTI-1, topotecan, irinotecanetoposide, teniposide, geldanamycin, methotrexate, adriamycin, actinomycin D, medroxyprogesterone, mifepristone, raloxifene, 5-azacytidine, 5-aza-2'-deoxycytidine, zebularine, tamoxifen, 4-hydroxytamoxifen, apigenin, rapamycin, angiostatin K1-3, L-asparaginase, staurosporine, genistein, fumagillin, endostatin, isophosphoramide mustard, thalidomide and analogs thereof. 11. The method of claim 8, further comprising administering a third compound to the subject, wherein the third compound is selected from the microtubule binding agents, DNA intercalators or cross-linkers, DNA synthesis inhibitors, DNA and/or RNA transcription inhibitors, enzyme inhibitors, gene regulators, enzymes, antibodies and angiogenesis inhibitors. 12. The method of claim 1, wherein administering comprises directly administering the compound to a tumor. 13. A method for treating a subject having brain and/or breast cancer, comprising administering to the subject a therapeutically effective amount of a compound of the formula ##STR00020## or a pharmaceutically acceptable salt thereof, wherein R is a lower alkyl group optionally substituted with halogen. 14. The method of claim 13, comprising administering from about 1 mg/m.sup.2 to about 200 mg/m.sup.2 to the subject per day. 15. The method of claim 13, wherein the treating comprises treating a brain tumor. 16. The method of claim 13, wherein the method comprises treating the subject for at least one of metastatic breast cancer and leukemia to the brain. 17. The method of claim 13, further comprising administering a second compound to the subject, wherein the second compound is selected from microtubule binding agents, DNA intercalators, DNA alkylating agents, DNA cross-linkers, DNA synthesis inhibitors, DNA and/or RNA transcription inhibitors, enzyme inhibitors, gene regulators, enzymes, antibodies and angiogenesis inhibitors.

Details for Patent 9,884,051

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2025-12-13